

Special Issue

Molecular Research in Genitourinary Oncology

Message from the Guest Editors

Genitourinary oncology encompasses cancers of the prostate, bladder, kidney, testis, and penis, where molecular research is driving transformative advances in diagnosis, prognosis, and therapy. This Special Issue will highlight cutting-edge studies that elucidate tumor biology, immune interactions, and microenvironmental influences that may affect genitourinary malignancies. Emphasis areas include genomic and epigenomic profiling to identify driver mutations, actionable targets, and predictive biomarkers. Our Special Issue is interested in novel translational research exploring new targeted agents, immunotherapies, combination regimens, and mechanisms of resistance, including the development of liquid biopsies (circulating tumor DNA, exosomes) and advanced imaging biomarkers for early detection and disease monitoring. By assembling multidisciplinary perspectives, the Special Issue aims to accelerate precision medicine in genitourinary cancers, foster biologically informed clinical trials, and chart future directions for improving patient outcomes.

- Keywords:

- Genitourinary oncology
- Molecular biomarkers
- Genomics and epigenomics
- Tumor microenvironment
- Liquid biopsy

Guest Editors

Dr. Ilias Giannakodimos

Dr. Ioannis Zachos

Dr. Vassilios P. Tzortzis

Deadline for manuscript submissions

31 March 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/258821

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).